Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)

Michael M. Altaweel, Ebenezer Daniel, Daniel F. Martin, Robert A. Mittra, Juan E. Grunwald, Michael M. Lai, Alexander Melamud, Lawrence S Morse, Jiayan Huang, Frederick L. Ferris, Stuart L. Fine, Maureen G. Maguire

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Design Prospective cohort study within a multicenter randomized clinical trial. Participants CATT patients with neovascular age-related macular degeneration (AMD). Methods Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. Main Outcome Measures Morphologic features and VA at 1 and 2 years. Results The B50 group consisted of 84 of 1185 (7.1%) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455 μm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. Conclusions In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50% blood can be managed similarly to those with less or no blood.

Original languageEnglish (US)
Pages (from-to)391-398.e5
JournalOphthalmology
Volume122
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Macular Degeneration
Visual Acuity
Choroidal Neovascularization
Fluorescein Angiography
Optical Coherence Tomography
Blood Group Antigens
Reading
Cohort Studies
Therapeutics
Randomized Controlled Trials
Color
Outcome Assessment (Health Care)
Prospective Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Altaweel, M. M., Daniel, E., Martin, D. F., Mittra, R. A., Grunwald, J. E., Lai, M. M., ... Maguire, M. G. (2015). Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology, 122(2), 391-398.e5. https://doi.org/10.1016/j.ophtha.2014.08.020

Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT). / Altaweel, Michael M.; Daniel, Ebenezer; Martin, Daniel F.; Mittra, Robert A.; Grunwald, Juan E.; Lai, Michael M.; Melamud, Alexander; Morse, Lawrence S; Huang, Jiayan; Ferris, Frederick L.; Fine, Stuart L.; Maguire, Maureen G.

In: Ophthalmology, Vol. 122, No. 2, 01.02.2015, p. 391-398.e5.

Research output: Contribution to journalArticle

Altaweel, MM, Daniel, E, Martin, DF, Mittra, RA, Grunwald, JE, Lai, MM, Melamud, A, Morse, LS, Huang, J, Ferris, FL, Fine, SL & Maguire, MG 2015, 'Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)', Ophthalmology, vol. 122, no. 2, pp. 391-398.e5. https://doi.org/10.1016/j.ophtha.2014.08.020
Altaweel, Michael M. ; Daniel, Ebenezer ; Martin, Daniel F. ; Mittra, Robert A. ; Grunwald, Juan E. ; Lai, Michael M. ; Melamud, Alexander ; Morse, Lawrence S ; Huang, Jiayan ; Ferris, Frederick L. ; Fine, Stuart L. ; Maguire, Maureen G. / Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT). In: Ophthalmology. 2015 ; Vol. 122, No. 2. pp. 391-398.e5.
@article{9e1cae52b4d44d628629dd1bb14c9a6f,
title = "Outcomes of eyes with lesions composed of >50{\%} blood in the comparison of age-related macular degeneration treatments trials (CATT)",
abstract = "Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50{\%} of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Design Prospective cohort study within a multicenter randomized clinical trial. Participants CATT patients with neovascular age-related macular degeneration (AMD). Methods Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. Main Outcome Measures Morphologic features and VA at 1 and 2 years. Results The B50 group consisted of 84 of 1185 (7.1{\%}) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455 μm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. Conclusions In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50{\%} blood can be managed similarly to those with less or no blood.",
author = "Altaweel, {Michael M.} and Ebenezer Daniel and Martin, {Daniel F.} and Mittra, {Robert A.} and Grunwald, {Juan E.} and Lai, {Michael M.} and Alexander Melamud and Morse, {Lawrence S} and Jiayan Huang and Ferris, {Frederick L.} and Fine, {Stuart L.} and Maguire, {Maureen G.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.ophtha.2014.08.020",
language = "English (US)",
volume = "122",
pages = "391--398.e5",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)

AU - Altaweel, Michael M.

AU - Daniel, Ebenezer

AU - Martin, Daniel F.

AU - Mittra, Robert A.

AU - Grunwald, Juan E.

AU - Lai, Michael M.

AU - Melamud, Alexander

AU - Morse, Lawrence S

AU - Huang, Jiayan

AU - Ferris, Frederick L.

AU - Fine, Stuart L.

AU - Maguire, Maureen G.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Design Prospective cohort study within a multicenter randomized clinical trial. Participants CATT patients with neovascular age-related macular degeneration (AMD). Methods Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. Main Outcome Measures Morphologic features and VA at 1 and 2 years. Results The B50 group consisted of 84 of 1185 (7.1%) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455 μm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. Conclusions In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50% blood can be managed similarly to those with less or no blood.

AB - Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Design Prospective cohort study within a multicenter randomized clinical trial. Participants CATT patients with neovascular age-related macular degeneration (AMD). Methods Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. Main Outcome Measures Morphologic features and VA at 1 and 2 years. Results The B50 group consisted of 84 of 1185 (7.1%) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455 μm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. Conclusions In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50% blood can be managed similarly to those with less or no blood.

UR - http://www.scopus.com/inward/record.url?scp=84921613040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921613040&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.08.020

DO - 10.1016/j.ophtha.2014.08.020

M3 - Article

C2 - 25307130

AN - SCOPUS:84921613040

VL - 122

SP - 391-398.e5

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 2

ER -